FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Why Hims & Hers Stock Popped on Monday
Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...
Hims & Hers Health (HIMS): Among the Stocks That Outperform the Broader Market
We recently published a list of 15 Stocks That Outperform the S&P 500 Every Year For the Last 3 Years. In this article, we are going to take a look at where Hims & Hers Health, Inc.
The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin
DaVita has experienced difficulty enrolling more patients in its dialysis program, reporting a decline in its patients since ...
Hims & Hers app download pace accelerated in February, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach reports that third party data suggests 47% year-over-year growth in app downloads in the month of ...
The weight loss drug shortage is over — and some patients are 'panicking'
For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...